Hydra Biosciences Inc., which specializes in transient receptor potential channel modulation, and Boehringer Ingelheim have started a collaboration and license agreement to identify small-molecule TRP inhibitors, with a primary focus on the treatment of renal diseases and disorders.

The two companies last year began collaborating to research and develop small-molecule TRPC4/5 inhibitors for the treatment of central nervous system diseases and disorders.

Under the terms of the collaboration agreement, the companies will work together to identify and advance candidate inhibitors. Boehringer Ingelheim is responsible for the global development and commercialization of the inhibitors that come from the collaboration. Hydra will receive an undisclosed upfront payment, additional research funding, and the company is eligible to receive milestone payments and tiered royalty payments on future product sales.